Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Futura Medical ( (GB:FUM) ) is now available.
Futura Medical announced it will release its interim results for the first half of 2025 on September 30, accompanied by a webinar for existing and potential shareholders. The presentation will be hosted via the Investor Meet Company platform, allowing for pre-submitted and live questions. This announcement underscores Futura’s commitment to transparency and engagement with stakeholders, potentially strengthening its market position as it continues to innovate in the sexual health industry.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their core strength lies in research, development, and commercialization of topically delivered gel formulations. The company’s lead product, Eroxon, is a topical gel treatment for erectile dysfunction (ED) and is notable for being the only over-the-counter treatment of its kind. Futura also has products in development, including WSD4000 for women’s sexual health, addressing significant unmet needs in the market.
Average Trading Volume: 1,157,124
Technical Sentiment Signal: Sell
Current Market Cap: £11.86M
For an in-depth examination of FUM stock, go to TipRanks’ Overview page.